CAI
Caris Life Sciences, Inc. Common Stock
NASDAQ: CAI · HEALTHCARE · BIOTECHNOLOGY
$15.94
-4.57% today
Updated 2026-06-05
Market cap
$5.08B
P/E ratio
—
P/S ratio
5.60x
EPS (TTM)
$-2.76
Dividend yield
—
52W range
$14 – $43
Volume
2.5M
WallStSmart proprietary scores
44
out of 100
Grade: D
Sell
Investment rating
8.0
Growth
A7.0
Quality
B+5.0
Profitability
C+5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-0.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$27.83
+74.59%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy10 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $22.53M — positive
+ Revenue growth 78.80% QoQ
+ Debt/equity 0.00x — low leverage
Risks
- Altman Z -0.92 — distress zone
- Thin margins at 3.75%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $258.49M | $306.13M | $412.26M | $812.03M | $907.29M |
| Net income | $-320.83M | $-341.42M | $-281.89M | $-537.96M | $-510000.00 |
| EPS | — | — | — | — | $-2.76 |
| Free cash flow | $-327.96M | $-298.42M | $-253.64M | $66.89M | $22.53M |
| Profit margin | -124.12% | -111.53% | -68.38% | -66.25% | 3.75% |
Peer comparison
Smart narrative
Caris Life Sciences, Inc. Common Stock trades at $15.94. Our Smart Value Score of 44/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -0.92, it sits in the distress. TTM revenue stands at $907.29M. with profit margins at 3.75%.
Frequently asked questions
What is Caris Life Sciences, Inc. Common Stock's stock price?
Caris Life Sciences, Inc. Common Stock (CAI) trades at $15.94, on a P/S of 5.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Caris Life Sciences, Inc. Common Stock overvalued?
Caris Life Sciences, Inc. Common Stock carries a Smart Value Score of 44/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Caris Life Sciences, Inc. Common Stock (CAI)?
The 12-month analyst consensus target is $27.83, about 74.6% above the current $15.94. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Caris Life Sciences, Inc. Common Stock's revenue?
Caris Life Sciences, Inc. Common Stock's trailing twelve-month revenue is $907.29M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Caris Life Sciences, Inc. Common Stock's Altman Z-Score is -0.92, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.60x
ROE5.73%
Beta—
50D MA$17.83
200D MA$24.29
Shares out0.28B
Float0.10B
Short ratio—
Avg volume2.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—